New arthritis drug shows promise in Long-Term safety trial

NCT ID NCT07223138

ENROLLING_BY_INVITATION Disease control Sponsor: MoonLake Immunotherapeutics AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with psoriatic arthritis. About 1560 adults who finished an earlier study will receive the drug as a shot under the skin. Researchers will track side effects and how well the drug controls arthritis symptoms over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTHRITIS, PSORIATIC

Contacts and locations

Locations

Clinical Site

Avondale, Arizona, 85392, United States
Clinical Site

Mesa, Arizona, 85210, United States
Clinical Site

Phoenix, Arizona, 85032, United States
Clinical Site

Tucson, Arizona, 85748, United States
Clinical Site

Jonesboro, Arkansas, 72401, United States
Clinical Site

Upland, California, 91786, United States
Clinical Site

Avon Park, Florida, 33825, United States
Clinical Site

Clearwater, Florida, 33765, United States
Clinical Site

Tampa, Florida, 33607, United States
Clinical Site

Charlotte, North Carolina, 28262, United States
Clinical Site

Leland, North Carolina, 28451, United States
Clinical Site

Middleburg Heights, Ohio, 44130, United States
Clinical Site

Duncansville, Pennsylvania, 16635, United States
Clinical Site

Memphis, Tennessee, 38119, United States
Clinical Site

Baytown, Texas, 77521, United States
Clinical Site

Lubbock, Texas, 79424, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.